ALL vs RARE · P/E 4.9, rev $18.60B vs rev $350.0M
The Allstate Corporation (ALL) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
The Allstate Corporation (ALL) is a insurance - property & casualty company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported ALL revenue for 2026-06-30 was $18.60B. Net income was $3.27B. Revenue was up 9.8% from 2026-03-31 to 2026-06-30. ALL currently screens at market cap $56.89B and trailing P/E 4.9.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
ALL currently screens at market cap $56.89B and trailing P/E 4.9. RARE currently screens at market cap $2.79B.
Not investment advice. Open the ALL and RARE stock pages for the full models.
Not investment advice.